ORIENT BIO Inc.

KRX:002630.KS

445 (KRW) • At close November 12, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) KRW.

202320222021202020192018201720162015201420132012201120102009200820072006
Revenue 28,819.0328,819.02826,276.46252,020.40537,699.31330,373.354121,207.763109,019.002105,049.54693,709.38183,722.28176,980.37252,052.58248,171.31144,736.56142,803.18943,857.14122,451.71
Cost of Revenue 18,994.5818,994.58417,262.89332,792.930,499.74127,362.556106,283.139100,648.06488,964.05477,161.90670,482.19459,229.68237,430.88538,073.04932,987.35330,401.85629,608.97614,624.422
Gross Profit 9,824.459,824.4449,013.56919,227.5057,199.5723,010.79714,924.6248,370.93816,085.49216,547.47513,240.08817,750.6914,621.69710,098.26211,749.20812,401.33314,248.1657,827.288
Gross Profit Ratio 0.3410.3410.3430.370.1910.0990.1230.0770.1530.1770.1580.2310.2810.210.2630.290.3250.349
Reseach & Development Expenses 1,801.331,801.3252,594.9462,645.2731,406.216655.2782,000.1781,162.56576.227551.162426.193704.0771,604.4521,405.2991,482.8471,346.631,216.1330.793
General & Administrative Expenses 697.599669.969618.5361,306.3943,058.4154,447.8731,956.9521,749.541,830.2261,702.091,168.7091,178.4331,269.324998.866830.118962.416874.716723.35
Selling & Marketing Expenses 3,088.982,338.3851,885.4392,179.4691,779.8011,953.464,686.6874,610.564,328.9923,429.8932,917.2683,023.9652,357.6033,071.1422,500.0631,616.0942,527.3691,846.989
SG&A 5,984.143,008.3532,503.9753,485.8634,838.2156,401.3336,643.6396,360.16,159.2195,131.9834,085.9784,202.3973,626.9274,070.0083,330.1812,578.513,402.0852,570.339
Other Expenses -28,375.787-245.351194.38427.789120.94116.323-203.671-2,566.7452,320.016-44.286-1,976.691-310.5298,969.12120.028-10,702.02252.034-2,111.263-4.758
Operating Expenses 8,371.648,371.63712,794.32317,368.00118,448.84712,243.51421,487.36217,658.74515,974.11115,643.49115,038.29114,255.95514,200.49913,089.80714,112.07910,239.29111,613.4426,671.153
Operating Income 1,452.811,452.807-3,780.7541,859.505-11,249.275-10,123.767-6,562.738-9,287.807111.38903.984-1,798.2043,494.735-10,343.741-2,991.544-2,362.872,162.0442,634.7261,156.134
Operating Income Ratio 0.050.05-0.1440.036-0.298-0.333-0.054-0.0850.0010.01-0.0210.045-0.199-0.062-0.0530.0510.060.051
Total Other Income Expenses Net -14,043.54-14,043.539419.549-17,618.069-394.746-3,949.216-9,647.983-13,484.119-2,742.294-2,724.35-8,436.278-2,091.416-9,983.3355,163.199-10,309.749-2,278.357-4,774.76-629.403
Income Before Tax -12,590.73-12,590.732-3,361.205-15,667.849-11,644.022-13,181.933-16,210.72-22,771.926-2,630.914-1,820.366-10,234.4821,403.319-9,562.1372,171.654-12,672.62-116.315-2,140.037526.732
Income Before Tax Ratio -0.437-0.437-0.128-0.301-0.309-0.434-0.134-0.209-0.025-0.019-0.1220.018-0.1840.045-0.283-0.003-0.0490.023
Income Tax Expense -167.02-167.02469.125-34.4421,660.515,256.143-3,640.9682,068.926-115.146-34.275-16.569128.267-762.058-43.206-16,839.274323.705622.078672.101
Net Income 8,410.922-12,423.70834,198.169-15,633.538-10,880.762-19,505.95-13,865.151-19,126.521-3,009.261-1,749.195-9,550.821878.817-10,601.9394,066.486-579.886-622.871-4,556.272526.732
Net Income Ratio 0.292-0.4311.301-0.301-0.289-0.642-0.114-0.175-0.029-0.019-0.1140.011-0.2040.084-0.013-0.015-0.1040.023
EPS 70.94-104.78-13.15-138.07-105.42-251.44-82.87-116.7-45.93-14.9-89.396.68-10741.42-5.58-7.17-74.088.76
EPS Diluted 70.94-104.78-13.15-138.07-105.42-251.44-82.87-116.7-45.43-14.9-89.396.68-10741.42-5.58-7.17-74.088.76
EBITDA -370.666,612.7821,624.1032,767.316-4,575.209-2,222.901-561.862-4,887.1978,160.9957,760.1321,391.6747,102.371-1,898.9451,085.511-7,860.8275,699.0557,185.1573,407.541
EBITDA Ratio -0.0130.2290.0620.053-0.121-0.073-0.005-0.0450.0780.0830.0170.092-0.0360.023-0.1760.1330.1640.152